NorthCrest Asset Manangement LLC Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

NorthCrest Asset Manangement LLC bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 14,890 shares of the biopharmaceutical company's stock, valued at approximately $448,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vermillion Wealth Management Inc. acquired a new stake in shares of TG Therapeutics during the fourth quarter worth approximately $30,000. Quadrant Capital Group LLC lifted its stake in TG Therapeutics by 137.1% in the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock valued at $51,000 after acquiring an additional 975 shares during the last quarter. Blue Trust Inc. lifted its stake in TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 371 shares during the last quarter. Smartleaf Asset Management LLC raised its position in shares of TG Therapeutics by 512.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 1,594 shares during the period. Finally, Jones Financial Companies Lllp raised its position in shares of TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 1,737 shares during the period. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Stock Performance

Shares of NASDAQ:TGTX traded down $0.39 during trading on Friday, hitting $35.32. 1,825,344 shares of the stock were exchanged, compared to its average volume of 2,979,020. The company has a market capitalization of $5.61 billion, a price-to-earnings ratio of -353.16 and a beta of 2.21. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. TG Therapeutics, Inc. has a 1-year low of $15.16 and a 1-year high of $46.48. The company's fifty day simple moving average is $37.40 and its 200-day simple moving average is $34.43.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. During the same quarter in the prior year, the firm earned ($0.07) EPS. The firm's quarterly revenue was up 90.4% on a year-over-year basis. Sell-side analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Wall Street Zen raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $40.80.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.